Wegovy FlexTouch 1.7 Mg Solution for Injection in Pre-filled Pen (3ml)

Wegovy FlexTouch 1.7 Mg Solution for Injection in Pre-filled Pen (3ml)

Wegovy FlexTouch 1.7 mg Solution for Injection in Pre-filled Pen (3 ml) is a prescription medication used for weight management in adults with obesity or overweight who have at least one weight-related health condition. It contains semaglutide, a GLP-1 analogue, and is given as a once-weekly subcutaneous injection.

Active ingredient

Semaglutide 2.27 mg/mL
Each pre-filled pen contains 6.8 mg semaglutide in 3 mL solution, delivering four weekly doses of 1.7 mg each.

Indications

• Used alongside a reduced-calorie diet and increased physical activity for weight management in adults with:

  • BMI ≥30 kg/m² (obesity)

  • BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidemia)

Dosage and administration

• Inject 1.7 mg subcutaneously once weekly, on the same day each week

• Each FlexTouch pen provides four weekly doses; use a new needle for each injection

• Injection sites: abdomen, thigh, or upper arm

Warnings and precautions

• Not recommended for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

• Use caution in patients with a history of pancreatitis, diabetic retinopathy, or severe gastrointestinal disease

• Inform your doctor if you are taking other diabetes medications

Common side effects

• Nausea, vomiting, diarrhea, constipation, abdominal pain, headache

• Side effects are most common at the start of treatment and usually decrease over time

Storage

• Store in a refrigerator (2°C–8°C). Do not freeze

• After first use, the pen can be kept at room temperature (below 30°C) for up to 6 weeks

• Keep out of reach of children

Brand: Wegovy
Manufacturer: Novo Nordisk

Made in: Denmark